Intuitive Surgical: My Sell Case Is Losing Ground (Rating Upgrade)
📈 Intuitive Surgical (ISRG) is upgraded to a Hold rating as the sell case loses ground due to lower multiples and resilient earnings offering better risk-return balance.
💰 Q2 revenue growth moderated to 18.5%, while operating income surged 30.7% with expanded margins even after adjusting for tariff refunds.
🔄 Recurring revenue from instruments, services, and leases drove 86% of incremental sales, highlighting the strength of the installed base.
🏥 Strong system adoption and installed base growth continue to support future procedure volumes and long-term demand.
⚖️ The analyst previously held a bullish view in June but now emphasizes that current valuation demands strong execution to justify the price.
Bullish Signals
- Operating income surged 30.7% in Q2, demonstrating resilient earnings despite moderate revenue growth.
- Margins expanded during the quarter even after adjusting for tariff refunds, indicating operational efficiency.
- Recurring revenue from instruments, services, and leases drove 86% of incremental sales, providing stable cash flow.
- System adoption and installed base growth are supporting future procedure volumes, ensuring long-term demand.
Risk Factors
- Revenue growth moderated to 18.5%, indicating a slowdown in top-line expansion compared to previous periods.
- Current valuation levels are considered high, requiring strong execution to justify the price for investors.
Full Analysis
Intuitive Surgical (ISRG) is being re-evaluated as a compelling long-term investment, though the analyst notes that current valuation levels require strong execution to justify the price. The company's Q2 financial performance showed revenue growth moderating to 18.5%, while operating income surged by 30.7% and margins expanded even after adjusting for tariff refunds.
The business model is driven significantly by recurring revenue from instruments, services, and leases, which accounted for 86% of incremental sales. This recurring nature is supported by strong system adoption and installed base growth, which in turn support future procedure volumes. The analyst concludes that while lower multiples offer a better risk-return balance, the stock has been upgraded to a Hold rating.
The upgrade reflects a shift from a previous bullish stance taken in June, where the analyst liked the company's hospital relationships and surgical platform but was concerned about the price. The current view suggests that while procedure growth and demand require close monitoring, the resilient earnings and lower multiples present an improved opportunity compared to the higher valuation previously observed.
